Waters stock price target lowered to $330 from $375 at BofA Securities

BofA Securities lowered its price target on Waters Corp. (WAT) to $330 from $375, maintaining a Neutral rating, citing valuation concerns over the company's recently announced $17.5 billion merger with Becton Dickinson's Biosciences & Diagnostic Solutions business, deeming the 19x valuation for the BDX transaction as rich. This downgrade follows a 14% share price decline for Waters and reflects BofA's caution regarding the combined entity's growth/margins and Waters' premium valuation. Conversely, Scotiabank and Bernstein SocGen Group maintain Outperform ratings with higher price targets, emphasizing the merger's potential to double Waters' addressable market, drive EPS accretion, and capitalize on growth opportunities in areas like EV battery testing and biopharma.

Analysis

Waters Corp. (WAT) is at a pivotal strategic juncture following the announcement of a $17.5 billion merger with Becton Dickinson's Biosciences & Diagnostic Solutions division. The transaction is positioned to double Waters' total addressable market and is projected to be accretive to adjusted EPS in its first year. However, the market has responded with significant skepticism, reflected in a 14% single-day share price decline. This negative sentiment is articulated by BofA Securities, which cut its price target to $330 from $375, citing concerns that the 19x multiple paid for the BDX asset is "rich." BofA's new target is based on a lowered 17x pro-forma FY26 EV/EBITDA multiple for the combined entity, anticipating lower growth and margins post-merger. This cautious stance, which also points to Waters' existing "premium valuation" at a 28x P/E, starkly contrasts with bullish outlooks from other analysts. Scotiabank raised its target to $465, while Bernstein and KeyBanc reiterated Outperform/Overweight ratings with a $400 price target. The bull case hinges on strategic expansion into high-growth areas, including EV battery testing and the biologics sector, bolstered by recent acquisitions and product launches. This divergence creates a clear debate between the deal's long-term strategic potential and its near-term valuation and execution risks.

Key Decisions for Investors

• Investors should weigh the merger's long-term strategic potential, including a doubled addressable market and EPS accretion, against the significant valuation concerns and execution risks highlighted by BofA's downgrade and the sharp stock decline.
• The valuation of the combined entity is a critical point of contention; closely monitor management's justification for the 19x multiple paid for the BDX asset and any future guidance on post-merger margins and growth.
• The bull case rests heavily on expansion into new markets, so investors should track progress and milestones in the EV battery testing and biologics segments as key performance indicators.
• Given the merger is not expected to close until Q1 2026, consider if the current valuation adequately discounts the integration risk or presents a long-term entry point ahead of the strategic transformation.